SER

Serina Therapeutics, Inc. (SER) SWOT Analysis Analysis (2026)

Invetso Score: 4.4/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Strengths

Score: 5.8 (Moderate)

Negative cash conversion cycle of -95.9 days indicates working-capital efficiency that can outpace peers in converting sales into cash, despite weak profitability.

Current and quick ratios of 6.65x suggest exceptional near-term liquidity versus peers, reducing refinancing pressure and supporting operational flexibility.

Debt-to-equity of 0.17x remains conservative relative to leveraged peers, limiting balance-sheet strain and preserving capacity through cyclical volatility.

Weaknesses

Score:

ROIC of -1.16% signals value destruction versus profitable peers, implying capital deployment is structurally weaker and constrains long-term competitive positioning.

Net debt to EBITDA of 0.89x is manageable, but positive leverage still leaves SER less resilient than net-cash peers when margins or demand soften.

The absence of disclosed margin metrics limits peer comparison, yet the available return profile still indicates weaker earnings quality than stronger operators.

Opportunities

Score:

Working-capital efficiency can support faster cash reinvestment than peers, creating room to fund growth without proportionate external financing.

Low leverage relative to many peers leaves incremental balance-sheet capacity available if operating performance improves and capital allocation becomes more productive.

If profitability normalizes, the combination of strong liquidity and efficient cash conversion could translate into a sharper peer catch-up in returns.

Threats

Score:

Persistently negative ROIC threatens relative relevance because peers with positive returns can compound capital faster and widen structural gaps over time.

Without disclosed margin data, investors may focus on the weak return profile, which can keep SER at a valuation and positioning disadvantage versus peers.

Any deterioration in working-capital efficiency would matter disproportionately because the current advantage is already offset by subpar capital productivity.

Overall Score

Score:

SER shows strong liquidity and cash-conversion characteristics, but negative ROIC keeps its structural positioning below stronger peer groups overall.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Serina Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →